Please login to the form below

Not currently logged in
Email:
Password:

Positive results from Gardasil efficacy

Gardasil has been shown to hold an efficacy rate of 96 per cent when used to vaccinate against early cervical lesions, according to recent clinical trail results.

Gardasil has been shown to hold an efficacy rate of 96 per cent when used to vaccinate against early cervical lesions, according to recent clinical trail results.

Sanofi Pasteur MD announced results from recent clinical studies of HPV quadrivalent vaccine Gardasil on March 7.

Due to high efficacy rates across the three phase II/III trails, the independent Data and Safety Monitoring Board (DSMB) recommended the studies be stopped so female patients in the placebo group could be given the vaccine.

Professor Charles Lacey, lead investigator from the University of York's Hull York Medical School, said: "The new data confirm the benefit that quadrivalent vaccination can provide in addition to cervical cancer prevention both for women's health and for health authorities.

"Gardasil offers a wide spectrum of protection against genital diseases caused by HPV and both an early and sustained protection which translates into rapid individual and long-lasting socio-economic benefit."

Gardasil also has efficacy rates of 99 per cent when protecting against genital warts and 100 per cent against early and precancerous vulvar and vaginal lesions.

The new data pertaining to the clinical studies conducted by Lacey's research team was presented at the 20th European Congress of Obstetrics and Gynaecology in Lisbon, Portugal.

Gardasil has already been approved in 93 other countries and launched in 76 of them.

11th March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...

Infographics